• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

No Elevated Risk for Stroke Seen After COVID-19 Bivalent Vaccine Receipt

Medically reviewed by Judith Stewart, BPharm. Last updated on March 21, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, March 20, 2024 -- For Medicare beneficiaries aged 65 years and older, there is no evidence of elevated stroke risk immediately after vaccination with either brand of the COVID-19 bivalent vaccine, according to a study published in the March 19 issue of the Journal of the American Medical Association.

Yun Lu, Ph.D., from the U.S. Food and Drug Administration in Silver Spring, Maryland, and colleagues examined stroke risk after administration of either brand of the COVID-19 bivalent vaccine, COVID-19 bivalent vaccine plus a high-dose or adjuvanted influenza vaccine on the same day (concomitant administration), and influenza vaccine.

The researchers observed no significant associations between either brand of the COVID-19 bivalent vaccine and stroke outcomes during the one- to 21-day or 22- to 42-day risk window versus the 43- to 90-day control window among the 11,001 beneficiaries who experienced stroke after receiving either brand of the COVID-19 bivalent vaccine. There was a statistically significant association noted between vaccination and nonhemorrhagic stroke during the 22- to 42-day risk window for the BNT162b2 COVID-19 bivalent vaccine and between vaccination and transient ischemic attack during the one- to 21-day risk window for the mRNA-1273.222 COVID-19 bivalent vaccine among the 4,596 beneficiaries who experienced stroke after concomitant administration. A significant association was seen between vaccination and nonhemorrhagic stroke during the 22- to 42-day risk window among the 21,345 beneficiaries who experienced stroke after influenza vaccination.

"The study by Lu et al illustrates the value of a timely, well-designed analysis and has provided reassurance about the COVID-19 boosters," Kathryn M. Edwards, M.D., and Marie R. Griffin, M.D., M.P.H., from Vanderbilt University in Nashville, Tennessee, write in an accompanying editorial.

Several authors disclosed employment with Acumen.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted March 2024

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.